© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Tandem Diabetes Care, Inc. (TNDM) stock declined over -4.19%, trading at $18.31 on NASDAQ, down from the previous close of $19.11. The stock opened at $18.77, fluctuating between $18.10 and $19.05 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 18.77 | 19.05 | 18.10 | 18.31 | 1.59M |
| Sep 09, 2026 | 19.67 | 19.73 | 19.04 | 19.11 | 1.57M |
| Sep 08, 2026 | 19.51 | 20.62 | 19.34 | 19.88 | 1.64M |
| Sep 04, 2026 | 20.04 | 20.36 | 19.49 | 19.90 | 1.36M |
| Sep 03, 2026 | 20.71 | 20.91 | 20.03 | 20.43 | 1.59M |
| Sep 02, 2026 | 21.25 | 21.74 | 20.54 | 20.56 | 1.13M |
| Sep 01, 2026 | 21.98 | 22.21 | 21.08 | 21.28 | 919.25K |
| Aug 31, 2026 | 21.00 | 22.30 | 20.56 | 22.01 | 1.61M |
| Aug 28, 2026 | 21.40 | 21.77 | 21.22 | 21.43 | 921.79K |
| Aug 27, 2026 | 21.20 | 21.94 | 21.02 | 21.40 | 1.03M |
| Aug 26, 2026 | 21.24 | 21.59 | 21.02 | 21.37 | 1.12M |
| Aug 25, 2026 | 22.16 | 22.16 | 21.30 | 21.58 | 1.19M |
| Aug 24, 2026 | 22.40 | 23.00 | 22.06 | 22.22 | 1.06M |
| Aug 21, 2026 | 23.25 | 23.25 | 22.06 | 22.32 | 1.64M |
| Aug 20, 2026 | 23.11 | 23.53 | 22.22 | 22.57 | 1.78M |
| Aug 19, 2026 | 24.20 | 24.81 | 23.42 | 23.46 | 1.66M |
| Aug 18, 2026 | 22.16 | 24.10 | 22.10 | 23.73 | 2.59M |
| Aug 17, 2026 | 22.50 | 22.94 | 21.70 | 22.26 | 1.36M |
| Aug 14, 2026 | 22.92 | 22.92 | 22.36 | 22.72 | 1.68M |
| Aug 13, 2026 | 23.33 | 23.56 | 22.88 | 23.13 | 1.4M |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
| Employees | 2500 |
| Beta | 1.54 |
| Sales or Revenue | $747.72M |
| 5Y Sales Change% | 2.016% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |